BioSpace News Archive

Biosplice Therapeutics, Inc. announced that its collaboration with The Roskamp Institute, aimed at developing novel therapies for TBI using Biosplice’s promising small molecule DYRK inhibitors has been selected for funding by the DoD office of the Congressionally Directed Medical Research Programs.

Insights into the workings of an immune cell surface receptor, called PD-1, reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new study shows.

InkSpace Imaging proudly announces a major leap forward in advancing diagnostic imaging capabilities.

Structure Therapeutics Inc. (NASDAQ: GPCR) today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida.

Mabwell announced that it will present the clinical study results on the efficacy and safety of the novel Nectin-4-targeting ADC 9MW2821 for patients with recurrent or metastatic cervical cancer as focused plenary oral presentation at the Society of Gynecologic Oncology (SGO) annual meeting on women’s cancer to be held in San Diego, USA, from March 16-18, 2024.

Kane Biotech Inc. announces that at the Bioscience Association of Manitoba annual awards dinner held on March 7, 2024, Kane Biotech received the BAM Company of the Year award.

NurExone Biologic Inc., a pioneering biopharmaceutical company, finalized a lease and constructing agreement for nearly 200 square meters of laboratories and office space on the campus of the prestigious Israel Institute of Technology.

Akero Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,650,000 shares of common stock in this offering.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Fulcrum Therapeutics, Inc.® announced that the company granted non-statutory stock options to two new employees.